Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 15/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30172080 | 1.00 | TTK (0.46) | TTKPTK6MAPKAPK5MEN1MAPT | |
| SCHEMBL22123433 | 0.91 | TTK (0.46) | TTKPTK6MAPKAPK5MEN1MAPT | |
| SCHEMBL22122930 | 0.91 | TTK (0.49) | TTKPTK6MAPKAPK5 | |
| SCHEMBL22122827 | 0.90 | TTK (0.45) | TTKPTK6MAPKAPK5MEN1MAPT | |
| SCHEMBL22123443 | 0.88 | TTK (0.48) | TTKPTK6MAPKAPK5ABL1BCR | |
| SCHEMBL22124906 | 0.87 | TTK (0.46) | TTKPTK6ABL1BCR | |
| SCHEMBL30183333 | 0.86 | TTK (0.47) | TTKPTK6MEN1MAPTKMT2A | |
| SCHEMBL22122947 | 0.86 | TTK (0.47) | TTKPTK6MAPKAPK5ABL1BCR | |
| SCHEMBL22122864 | 0.86 | TTK (0.46) | TTKPTK6MAPKAPK5ABL1BCR | |
| SCHEMBL22124678 | 0.86 | TTK (0.46) | TTKPTK6ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | TTK 4573/4885PTK6 2141/4885MAPKAPK5 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.